Abstract: The present disclosure provides a composition and a method both for improving the hair. In one embodiment, the hair is improved using an antibody. In one embodiment, the antibody is produced using a bacterium occurring on the scalp or a hair root as an immunogen. In one aspect, the present invention also provides a method for improving the hair in a subject, including the step of administering an antibody produced using a microorganism-derived substance as an immunogen to the subject. The antibody according to the present invention may be administered in the form of a composition. According to the present invention, the promotion of hair growth or the prevention of hair loss can be achieved.

Abstract: There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain comprising three complementarity determining regions (CDR1-CDR3) and four framework regions, wherein: (a) at least one lysine residue in CDR1, CDR2 and/or CDR3 has been substituted with at least one histidine residue, and/or (b) at least one arginine residue in CDR1, CDR2 and/or CDR3 has been substituted with at least one histidine residue; wherein the polypeptide has increased intestinal stability relative to a corresponding polypeptide not having said histidine substitutions.

Abstract: The invention relates to an anti-CGRP antibody for use in the prevention and/or treatment of chronic pain and/or symptoms of chronic pain, and to a method of treating and/or preventing chronic pain and/or symptoms of chronic pain using an anti-CGRP antibody.

Abstract: The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease.

Abstract: In one aspect, methods of generating human monoclonal antibodies that specifically binds to an allergen are provided. In some embodiments, the monoclonal antibodies are generated from sequences identified from isolated single B cells from a human subject who is allergic to the allergen.

Abstract: In one aspect, methods of generating human monoclonal antibodies that specifically binds to an allergen are provided. In some embodiments, the monoclonal antibodies are generated from sequences identified from isolated single B cells from a human subject who is allergic to the allergen.

Abstract: Antibodies 9-10.2 and 8-4.1 that recognize YFGKLESK, which is 8 amino acids present in a neoepitope formed as a result of a precursor pro-IL-18 being cleaved by caspase-1 or caspase-4 are prepared. Accordingly, an antibody that recognizes only activated IL-18 can be provided.

Abstract: The present invention relates to anti-IL-23p19 binding compounds, in particular new humanized anti-IL-23p19 antibodies, pharmaceutical compositions and therapeutic and diagnostic methods and compositions for using the same.

Abstract: The present invention relates to a method for treating or alleviating the symptoms of peripheral arterial disease (PAD) in a subject, comprising administering about 25 mg to about 300 mg of an IL-1? binding antibody or functional fragment thereof.

Abstract: The present invention relates to methods for preventing or treating head and neck spuamous cell cancer and bladder cancer using an immunotoxin comprising (a) a ligand that binds to a protein on the cancer cell attached to; (b) a toxin that is cytotoxic to the cancer cell. In a specific embodiment, the invention is directed to the prevention or treatment of head and neck squamous cell cancer or bladder cancer using Vb4-845, which is a recombinant immunotoxin comprising a humanized, MOC31-derived, single-chain antibody fragment that is fused to a truncated form of Pseudomonas exotoxin A. Also encompassed by the invention are combination therapy methods, including the use of reduced dosages of chemotherapeutic agents, for the prevention or treatment of cancer. Also encompassed by the invention are formulations and methods for direct administration of the recombinant immunotoxin to the carcinoma, for the prevention or treatment of cancer.

Abstract: The present invention relates to bi-specific antigen binding molecules and associated fusion proteins and conjugates. In particular, the present invention relates to bi-specific antigen binding molecules with specificity for both receptor tyrosine kinase-like orphan receptor 1 (ROR1) and epidermal growth factor receptor (EGFR) and associated fusion proteins and conjugates. In a further aspect, the present invention relates to conjugated immunoglobulin-like shark variable novel antigen receptors (VNARs).

Abstract: This invention relates generally to monoclonal antibodies that recognize CD47, more specifically to CD47 antibodies that do not cause a significant level of agglutination of cells, red blood cell depletion, anemia, and/or platelet depletion, to methods of generating these antibodies, and to methods of using these monoclonal antibodies as therapeutics.

Abstract: The invention provides agonistic anti-human VISTA antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.

Abstract: The invention provides agonistic anti-human VISTA antibodies and antibody fragments. These agonist antibodies and antibody fragments may be used to potentiate or enhance or mimic VISTA's suppressive effects on T cell immunity and thereby suppress T cell immunity. These agonist antibodies and antibody fragments are especially useful in the treatment of autoimmunity, allergy, inflammatory conditions, GVHD, sepsis and transplant recipients. Screening assays for identifying these agonists are also provided.

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a CD33 polypeptide, e.g., a mammalian CD33 or human CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Abstract: Provided herein are CD79b antibodies and CD79b-specific chimeric antigen receptors (CARs). Further provided herein are T cells expressing the CD79b-specific CARs and methods of treating cancer by administering the CD79b-specific CAR T cells.

Abstract: Cytotoxic anti-LAG-3 monoclonal antibodies or fragments thereof causing depletion of LAG-3+ activated T cells are described, as are related pharmaceuticals and methods of treating. Also described are related nucleic acid and protein sequences.

Abstract: Provided herein are anti-TREM2 antibodies and related methods of making and using anti-TREM2 antibodies. Also provided are methods and compositions for enhancing an immune response and/or for the treatment of an immune-related condition in an individual, e.g., cancer, using an anti-TREM2 antibody or antigen binding fragment thereof.

Abstract: Disclosed herein are isolated multi-specific heteromultimer constructs that bind to CD3 expressed on T-cells and to an antigen expressed on B-cells. The multi-specific heteromultimer constructs are capable of bridging T- and B-cells and mediating killing of B-cells. The multi-specific heteromultimer constructs are based on a heterodimeric Fc scaffold or on a segmented albumin scaffold. Also disclosed herein are multi-specific heteromultimer constructs that bind to HER2 and HER3.

Abstract: Described herein are novel anti-CD3 Folate antibodies and uses thereof in the treatment of diseases or conditions that would benefit from such.

Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Lymphocyte-Activation Gene 3 (LAG3) antagonist, and the use of the combination therapies for the treatment of non-microsatellite instability-high (non-MSI-H) or proficient mismatch repair (pMMR) colorectal cancer.

Abstract: The invention provides methods for producing crystalline an anti-PD-1 monoclonal antibody (mAb), wherein the mAb is pembrolizumab or a pembrolizumab variant, comprising (1) mixing a solution comprising (a) the mAb, (b) polyethylene glycol (PEG), and (c) an additive selected from the group consisting of: caffeine, theophylline, 2? deoxyguanosine-5?-monophosphate, a bioactive gibberellin, and a pharmaceutically acceptable salt of said bioactive gibberellin, to form a crystallization solution, (2) incubating the crystallization solution for a period of time sufficient for crystal formation; and (3) optionally harvesting the crystalline anti-PD-1 mAb from the solution. In specific embodiments, the PEG is PEG 3350 and the additive is caffeine. The invention also relates to the novel anti-human PD-1 mAb crystals produced by the methods described herein.

Abstract: This invention relates to anti-FLT3 antibodies and methods of using them in enhancing immunity in a patient in need thereof and in treating cancer.

Abstract: The present invention belongs to the field of antibody drugs, and relates to a humanized anti-VEGFR2 single-chain antibody and use thereof. The single-chain antibody comprises a heavy chain variable region set forth in SEQ ID No. 1 and a light chain variable region set forth in SEQ ID No. 2, wherein the heavy chain variable region and the light chain variable region are connected via a flexible peptide with an amino acid sequence set forth in SEQ ID No. 3. The present invention also discloses use of the antibody in preparing a product for inhibiting tumor growth. The antibody disclosed herein can be used as a medicament for clinical use in indications caused by neovascularization.

Abstract: A method of reducing IL-4 and/or IL-13 levels in the lung of a mammal with elevated levels thereof, includes the step of administering to the mammal an effective amount of a ?c receptor blocker capable of blocking the binding of all three of IL-3, IL-5 and GM-CSF to the ?c common chain to thereby reduce the IL-4 and/or IL-13 levels.

Abstract: Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis.

Abstract: Methods for clinically proven safe administration of an anti-CD 154 antibody or antigen binding fragment thereof by subcutaneous or intravenous administration are provided. Also provided are methods for clinically proven safe treatment of an autoimmune disease by subcutaneous or intravenous administration of an anti-CD 154 antibody or antigen binding fragment thereof, such as rheumatoid arthritis, systemic lupus erythematosus (SLE), and Sjögren's Syndrome.

Abstract: Antagonistic TNFR superfamily polypeptides, such as antibodies and antigen-binding fragments thereof, and the use of these polypeptides to inhibit the proliferation of regulatory T cells (T-regs). For example, antibodies of the invention include antagonistic TNER2 antibodies and antigen-binding fragments thereof, and can be used to suppress the T-reg-mediated deactivation of tumor reactive T-lymphocytes, as well as to treat a wide variety of cancers and infectious diseases.

Abstract: The invention relates to antibodies specific for 4-1BB and OX40, as well as to methods for using such antibodies and therapeutic uses thereof.

Abstract: Multi-specific binding proteins that bind to and kill human cancer cells are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer. The cancer can be B-cell maturation antigen (BCMA)-expressing cancer. The multi-specific binding proteins provided herein exhibit high potency and maximum lysis of target cells compared to anti-BCMA monoclonal antibodies.

Abstract: Provided are bispecific and multi-specific antibodies that target both claudin 18.2 (CLDN18.2) and 4-1BB. These antibodies, in the absence of CLDN18.2-expressing cells, can bind to 4-1BB but are unable to activate 4-1BB signaling. In the presence of CLDN18.2-expressing cells, however, these antibodies can trigger CLDN18.2-dependent 4-1BB signaling, leading to potent immune response to the CLDN18.2-expressing tumor cells.

Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.

Abstract: Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload reduces glycogen levels in a cell.

Abstract: The present disclosure relates to compositions and methods of engineered Fc-antigen binding domain constructs, where the Fc-antigen binding domain constructs include at least two Fc domains and at least one antigen binding domain.

Abstract: The invention provides compositions and methods useful for the depletion of CD117+ cells and for the treatment of various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases, among others. Described herein are antibodies, antigen-binding fragments, and conjugates thereof that can be applied to effect the treatment of these conditions, for instance, by depleting a population of CD117+ cells in a patient, such as a human. The compositions and methods described herein can be used to treat a disorder directly, for instance, by depleting a population of CD117+ cancer cells or autoimmune cells. The compositions and methods described herein can also be used to prepare a patient for hematopoietic stem cell transplant therapy and to improve the engraftment of hematopoietic stem cell transplants by selectively depleting endogenous hematopoietic stem cells prior to the transplant procedure.

Abstract: The present invention provides EpCAM antibodies with different affinities. The present invention also provides chimeric antigen receptors (CARs) specific to EpCAM. CAR T cells comprising human EpCAM scFv having a low and sufficient affinity to EpCAM can avoid targeting healthy tissues with low EpCAM expression while exhibiting long-term efficacy against tumor tissues with high EpCAM expression. The present invention also relates to an adoptive cell therapy method for treating cancer by administering the CAR-T cells comprising human EpCAM scFv to a subject suffering from cancer, whereby the CAR T cells bind to the cancer cells overexpressing EpCAM and kill the cancer cells.

Abstract: Provided is a fusion protein, comprising a first binding domain that specifically binds a tumor-associated antigen, and a second binding domain that specifically binds a CD47 protein, wherein the second binding domain comprises a mutant of a human SIRP? variant 1. Also provided are an immunoconjugate, nucleic acid molecules, vectors, compositions, and cells related to the fusion protein and preparation methods therefor, and the uses thereof in the preparation of medicaments.

Abstract: The present invention relates to antibodies against the human 5T4 oncofoetal antigen and corresponding antibody-drug conjugates that are suitable for testing in clinical trials. The antibodies are cross-reactive for humans and cynomolgus monkeys and exhibit an affinity for human 5T4 antigen which is in the same order of magnitude as their affinity for cynomolgus monkey 5T4 antigen. The invention further relates to the use of the antibodies and corresponding ADCs in the treatment of solid tumours and haematological malignancies.

Abstract: Increasingly, human subjects are taking biotin as a medical therapy or nutritional supplement. This practice causes difficulty in analysis of biological samples, such as blood samples, using biotin conjugate reagents since free biotin results in interference. Inventive antibodies, and antigen binding fragments thereof, which specifically bind to biotin of a biotin conjugate and which have a higher affinity for biotin of a biotin conjugate than for free biotin, are provided along with methods of their use.

Abstract: The purpose of the present invention is to provide an efficient and versatile method for granting an additional binding activity to an antibody by inserting a peptide sequence into the antibody. The present invention provides a method of granting a binding ability to a second target molecule to an antibody, comprising inserting an internal peptide sequence of a cyclic peptide into an Fc region of the antibody, wherein the cyclic peptide has the binding ability to the second target molecule different from a first target molecule to be recognized by the antibody.

Abstract: The present invention provides a nanodisc with a membrane scaffold protein. The nanodisc includes a membrane scaffold protein, a telodendrimer and a lipid. The membrane scaffold protein can be apolipoprotein. The telodendrimer has the general formula PEG-L-D-(R)n, wherein D is a dendritic polymer; L is a bond or a linker linked to the focal point group of the dendritic polymer; each PEG is a poly(ethylene glycol) polymer, each R is and end group of the dendritic polymer, or and end group with a covalently bound hydrophobic group, hydrophilic group, amphiphilic compound, or drug; and subscript n is an integer from 2 to 20. Cell free methods of making the nanodiscs are also provided.

Abstract: Processes for precipitating a polymer from a polymer-containing fluid are disclosed, which include providing a vessel housing a medium that provides one or more precipitation surfaces. A polymer-containing fluid, e.g., a polymer solution, dispersion or mixed solution/dispersion, and an anti-solvent can be introduced into the vessel so as to cause precipitation of at least a portion of the polymer on at least one of the precipitation surfaces. In some embodiments, the polymer contains one or more cyclic oligosaccharide moieties, such as one or more cyclodextrin moieties (e.g., ?-cyclodextrin, ?-cyclodextrin, and ?-cyclodextrin). The polymer can be any of a linear or branched polymer. The polymer can be any of polycation, a polyanion, or a non-ionic polymer. Also disclosed herein are precipitation surfaces with polymer precipitated thereon.

Abstract: The present invention relates to a multi-stage process for producing a C2 to C8 olefin polymer composition in a process comprising at least two reactors, wherein a pre-polymerized solid Ziegler-Natta catalyst is prepared by carrying out an off-line pre-polymerization of a solid Ziegler-Natta catalyst component with a C2 to C4 olefin monomer before feeding to the polymerization process.

Abstract: The present disclosure relates to a method for preparing a super absorbent polymer that can appropriately control the water content of the super absorbent polymer by hydration or the like to suppress crushing or the like during transfer, and also can suppress deterioration of physical properties, such as production of giant particles and nonuniformity of water content during hydration step.

Abstract: The present invention relates to new bis(metallocene) compounds, new catalyst compositions, process for preparing the new bis(metallocene) compounds and use of said new catalyst compositions to polymerise olefins. The bis(metallocene) compounds of the invention are homo- or hetero bis(metallocene) molecules in which same or different metallocene moieties are connected by a phenylene bridge. The phenylene bridge is either para-substituted, meta-substituted or ortho-substituted by the two metallocene moieties.

Abstract: Disclosed are a novel metallocene catalyst and a method for preparing a polyolefin having a high molecular weight and a low melt index by using the same. The present invention provides a transition metal compound represented by formula 1.

Abstract: The present disclosure relates to a novel resin composition which imposes a reduced environmental load and which is excellent in dispersibility of fine polymer particles. Provided is a resin composition containing water, fine polymer particles (A) having a specific feature, and a thermosetting resin (B) having a specific feature. The resin composition contains the water, the fine polymer particles (A), and the thermosetting resin (B) in respective specific amounts, does not substantially contain an organic solvent, and contains sulfur (S) in an amount falling within a specific range and phosphorus (P) in an amount falling within a specific range.

Abstract: Embodiments of the invention relate to a resin composition, in particular suitable for printing, a kit comprising components of the resin composition, printing methods, a polymer obtained by the printing methods, an article comprising or formed from the polymer, uses thereof, and a composition. The resin composition comprises at least one compound C1 having at least one terminal alkyne functional group; at least one compound C2 having at least two thiol functional groups; at least one compound C3 having at least one carbon-carbon double bond; at least one photoinitiator; and at least one stabilizer.

Abstract: The present invention relates to a process for producing a prepolymerized solid Ziegler-Natta catalyst in batch mode, a prepolymerized solid Ziegler-Natta catalyst, a process for producing a propylene polymer using said prepolymerized solid Ziegler-Natta catalyst, a prepolymerized solid Ziegler-Natta catalyst obtained by a process as well as the use of the prepolymerized solid Ziegler-Natta catalyst in a process for producing a propylene polymer.

Abstract: The present disclosure provides a method of preparing a vinyl chloride-based polymer, and the method provides excellent productivity while having reduced amount of a volatile organic compound generated so as to provide the vinyl chloride-based polymer suitable for an eco-friendly material, and improved foaming and viscosity properties of a plastisol including the prepared polymer, by adding a carbonate-based metal salt and a transition metal catalyst together, and controlling input time and amount of the transition metal catalyst.